Loading clinical trials...

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer | Clinical Trials | Clareo Health

COMPLETEDPhase 1

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer

NCT02392611•Gilead Sciences

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Solid Tumors and Lymphomas

Interventions

Alobresib

Exemestane

+1 more

Locations

4

United States

Locations (4)

Scottsdale, Arizona, United States

Fort Wayne, Indiana, United States

Goshen, Indiana, United States

San Antonio, Texas, United States

Key Dates

Start Date

March 16, 2015

Primary Completion Date

October 11, 2017

Completion Date

October 11, 2017

Last Updated

December 29, 2020

Related Studies

TERMINATEDPhase 1

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

NCT03172936

Solid Tumors and Lymphomas

WITHDRAWNPhase 1

Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas

NCT00457574

Solid Tumors and Lymphomas

Sponsors

Lead Sponsor

Gilead Sciences

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 29, 2020Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions